Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0%

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw a significant increase in short interest in February. As of February 15th, there was short interest totalling 576,400 shares, an increase of 149.0% from the January 31st total of 231,500 shares. Based on an average trading volume of 281,000 shares, the short-interest ratio is currently 2.1 days.

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $2.09 on Friday. The business has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $2.36. Oramed Pharmaceuticals has a 1 year low of $2.00 and a 1 year high of $3.48. The company has a market capitalization of $84.25 million, a P/E ratio of 19.00 and a beta of 1.66.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 19th.

Institutional Trading of Oramed Pharmaceuticals

A number of large investors have recently bought and sold shares of ORMP. Murchinson Ltd. boosted its holdings in shares of Oramed Pharmaceuticals by 0.5% in the third quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock worth $4,170,000 after acquiring an additional 8,889 shares during the period. XTX Topco Ltd boosted its stake in Oramed Pharmaceuticals by 59.7% during the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 9,242 shares during the period. Boothbay Fund Management LLC boosted its stake in Oramed Pharmaceuticals by 2.0% during the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after buying an additional 16,857 shares during the period. World Equity Group Inc. bought a new stake in Oramed Pharmaceuticals during the fourth quarter valued at $48,000. Finally, Marquette Asset Management LLC bought a new stake in Oramed Pharmaceuticals during the fourth quarter worth about $81,000. 12.73% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.